Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Johnson & Johnson : Says Discounts Cut the Prices for Its Drugs, Though Revenue Rose

share with twitter share with LinkedIn share with facebook
share via e-mail
03/09/2018 | 12:39am CEST

By Jonathan D. Rockoff

Johnson & Johnson said Thursday the average price paid for its medicines in the U.S. fell by 4.6% last year due to the company's discounts, and the company's pharmaceuticals chief expects the pricing pressures on drugmakers will continue this year.

J&J, one of the biggest sellers of prescription drugs in the U.S., said it raised the list prices for its medicines by an average 8.1%, but they wound up as a whole costing far less because the manufacturer handed out $15 billion in discounts and rebates.

"That shows the level of competition that exists in the U.S. market," Joaquin Duato, who heads J&J's pharmaceuticals business, said in an interview.

Overall J&J's U.S. pharmaceutical sales still did well last year, rising 6.7% to $21.5 billion. Mr. Duato said that the increase stemmed from higher volume, not prices.

Several drugmakers provide aggregate pricing data each year partly to blunt public criticism of rising drug prices and shift focus to health-care companies like drug-benefit managers that can profit from the price increases as well as from raising the copays patients pay for medicines.

Merck & Co. said last month that the prices of its drugs and vaccines fell 1.9% in the U.S. last year after discounts and rebates.

Mr. Duato attributed the pricing squeeze to three factors that he expects to keep the drug industry's prices after discounts "flat" this year.

Health plans and drug-benefit managers are "more aggressive" restricting access to expensive drugs, and drug companies are required to provide discounts to growing numbers of patients in Medicaid and hospitals in a drug-discount program known as 340(b), Mr. Duato said.

Lower-priced competition is also starting to have an impact on the pricing of biotechnology drugs, Mr. Duato said, as rivals start launching so-called biosimilar copies.

J&J's aggregate drug pricing last year reflected the impact of such competition for rheumatoid-arthritis treatment Remicade, which has been the company's top-selling product but began facing competition from a copy sold by Pfizer Inc. in late 2016.

Remicade's U.S. sales fell $317 million to $4.5 billion last year.

Remicade competition was a "big factor" in J&J's average net price drop last year "but it wasn't the only factor," Mr. Duato said. The average price for J&J's prescription drugs after discounts was negative in 2017 excluding Remicade, he said.

Some analysts had expected a bigger drop in U.S. Remicade sales than what J&J experienced, but said J&J had managed to hold on to much of its Remicade business in the U.S. by offering deep discounts and other perks to limit switching to the rival drug.

Pfizer has sued J&J alleging it thwarted the "biosimilar" competition through "exclusionary contracts" with health insurers, hospitals and clinics. J&J has said the lawsuit lacks merit.

Write to Jonathan D. Rockoff at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
04:05pJOHNSON & JOHNSON : to Host Investor Conference Call on Second-Quarter Results
06/18MARKETS RIGHT NOW : Stocks look to recover from early skid
06/18JOHNSON & JOHNSON : FDA Approves the Next Generation of Customized LASIK Treatme..
06/18JOHNSON & JOHNSON : Janssen Pharmaceutical - XARELTO Associated with Significant..
06/16JOHNSON & JOHNSON : Gift Provides Undergraduate Financial Aid and Serves Communi..
06/15JOHNSON & JOHNSON : XARELTO (rivaroxaban) Associated With Significantly Reduced ..
06/15JOHNSON & JOHNSON : XARELTO (rivaroxaban) Associated with Significantly Reduced ..
06/15KYROS LAW IS INVESTIGATING CLAIMS ON : 1,100 Invokana Lawsuits Alleging Diabetic..
06/14JOHNSON & JOHNSON : Innovation Announces Five-Year Alliance with Boston Universi..
06/14JOHNSON & JOHNSON : IMBRUVICA® ibrutinib in Combination with Rituximab Showed Gr..
More news
News from SeekingAlpha
09:21aDIVIDEND SENSEI'S PORTFOLIO UPDATE 3 : 3 Reasons You Should Avoid This Dangerous.. 
07:39aThe Market Needs A Glum Index - Cramer's Mad Money (6/18/18) 
06:39aReaders Wrote-Up 37 Dividend Stocks In May-June Comments 
06/18Jane's May Dividend Income Tracker - Retirement Accounts 
06/18The No. 1 Stock In The World (Redux) - Part 2 
Financials ($)
Sales 2018 81 525 M
EBIT 2018 24 885 M
Net income 2018 16 158 M
Debt 2018 10 673 M
Yield 2018 2,97%
P/E ratio 2018 17,57
P/E ratio 2019 16,22
EV / Sales 2018 4,16x
EV / Sales 2019 3,86x
Capitalization 329 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 144 $
Spread / Average Target 19%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 330
ROCHE HOLDING LTD.-14.81%184 168
AMGEN6.39%122 422